Professional Essentials · Free · No registration
Radiographic axial spondyloarthritis
A practical guide to the radiographic phenotype, treatment decisions, persistent symptoms and the vulnerable ankylosed spine.
Radiographic axial spondyloarthritis (r-axSpA), also called ankylosing spondylitis, combines an axial inflammatory phenotype with definite conventional-radiographic sacroiliitis. Spinal fusion is not required. The label identifies an imaging category, while treatment depends on present inflammation, structural limitations, associated manifestations, safety and the patient’s priorities.
1. Define the phenotype
The modified New York radiographic threshold is sacroiliitis of at least grade 2 bilaterally or grade 3–4 unilaterally. This finding must fit the clinical assessment; a vague report of “mild sacroiliitis” is insufficient. Review actual images when uncertainty matters, describe laterality and lesions, and preserve the distinction between radiographic grades and MRI or CT findings.
Assess spinal and hip symptoms, peripheral synovitis, enthesitis, dactylitis, psoriasis, eye inflammation and bowel disease. Record what is active, damaged or uncertain. Groin pain, reduced hip rotation and gait change deserve a separate hip assessment rather than automatic attribution to the lumbar spine.
Consider degenerative disease, osteitis condensans ilii, infection and other mimics. Syndesmophytes, osteophytes and DISH require morphological interpretation; coexistence is possible. HLA-B27 supports probability in context, while normal CRP does not exclude disease. An inherited diagnostic label should neither prevent reassessment nor be discarded solely because treatment has made current findings quiet.
Sacroiliac radiographs: grading and uncertainty → Professional access required
2. Separate inflammation and damage
Persistent pain can reflect inflammation, fixed restriction, hip pathology, degeneration, neuropathic mechanisms or altered pain processing. Several can coexist. A high symptom score describes burden; it does not identify its cause. Compare the current distribution, examination, laboratory trend and treatment exposure with the original inflammatory presentation.
ASDAS measures composite activity; BASDAI captures symptoms, BASFI functional difficulty and BASMI mobility. ASDAS below 1.3 denotes inactive disease; a decrease of at least 1.1 denotes clinically important improvement. Improvement and final state differ: a fall from 4.0 to 2.7 improves substantially but leaves high activity. Use consistent methods and correct CRP units.
Order MRI when uncertainty about inflammation would change treatment. A quiet sacroiliac scan does not explain every spinal or hip complaint. Structural scores such as mSASSS measure selected radiographic damage, not whole-person severity. In SURPASS, secukinumab did not demonstrate radiographic superiority over an adalimumab biosimilar; symptom improvement should not be advertised as guaranteed prevention or reversal of fusion.
For example, improved night pain and CRP with persistent longstanding neck restriction suggest a different next step from new inflammatory symptoms and rising CRP. Document both gains and remaining limitations. Ask which daily task matters most: turning to drive, putting on shoes or completing a work shift. That answer helps translate measurements into an achievable treatment or rehabilitation goal.
Activity, function and mobility measures → Professional access required
3. Combine rehabilitation and treatment
Exercise remains an active treatment alongside medication. The EULAR physical-activity update, published in 2026, supports integrating physical activity into routine inflammatory-arthritis care. Tailor mobility, strength, aerobic conditioning, posture and breathing work to capacity, structural restrictions and comorbidity. A useful prescription names the activity, starting dose, progression and review point.
Ask what prevents participation: pain, fear of movement, fatigue, transport, work demands or limited access to appropriate physiotherapy. Adjust the plan rather than recording a generic instruction to exercise. Marked ankylosis or osteoporosis requires particular care with loading and fall risk; forceful manipulation is inappropriate.
NSAIDs often provide initial symptomatic treatment. Record the agent, dose, duration, benefit and adverse effects; assess gastrointestinal, renal, blood-pressure and cardiovascular risks. The ASAS–EULAR pathway includes adequate trials of two NSAIDs when safe before usual escalation. Contraindication or intolerance is a reason to change the pathway. Persistent clinically important inflammation should not be left untreated while repeating an ineffective regimen.
Exercise, rehabilitation and NSAIDs → Professional access required
4. Choose and review targeted therapy
The 2026 ACR/SAA/SPARTAN posted summary treats TNF and IL-17 inhibitors as comparable initial biologic options, generally ahead of JAK inhibitors. These are class-level recommendations; select a molecule with the appropriate indication, regimen and safety profile. Methotrexate or sulfasalazine should not be added simply to treat persistent purely axial inflammation.
BSR guidance generally favors a monoclonal TNF inhibitor for recurrent uveitis. Significant psoriasis may favor IL-17 inhibition, whereas active IBD requires a bowel-effective strategy and argues against starting IL-17 inhibition. Coordinate competing domains with ophthalmology, dermatology or gastroenterology. A painful photophobic red eye needs prompt ophthalmic assessment regardless of the systemic treatment plan.
Review tuberculosis, hepatitis, vaccination, infection history and drug-specific precautions. FDA JAK warnings require attention to cardiovascular, malignancy, thrombotic and infection risk. The pivotal randomized safety population had rheumatoid arthritis and enriched cardiovascular risk; its absolute event rates are not individualized predictions for everyone with axSpA.
Set an efficacy review around three to four months. Before switching, verify actual exposure and distinguish intolerance, primary nonresponse, secondary loss of response and residual noninflammatory burden. The ASAS refractory-disease definition requires objective inflammatory activity and exclusion of noninflammatory explanations, not merely several unsuccessful prescriptions.
Nonresponse: reassessment before another switch → Professional access required
5. Protect the vulnerable spine
New focal spinal pain after even minor trauma in an ankylosed spine requires urgent fracture assessment. These injuries may be unstable despite little displacement or an initially intact neurological examination. Preserve the patient’s baseline alignment during transfer and avoid forced straightening or manipulation.
AO guidance emphasizes CT for suspected cervical fracture and imaging the remaining spine when a fracture is identified because separate injuries may coexist. MRI is urgent when neurological deficits require assessment for cord injury or epidural hematoma, and can clarify equivocal CT. An unrevealing plain film must not close a clinically concerning evaluation.
Spinal new bone can coexist with osteoporosis. Bone-microarchitecture research demonstrates that syndesmophytes do not establish healthy vertebral trabecular bone. Review fracture and fall history and inspect DXA quality: new bone may inflate lumbar measurements. ISCD positions guide exclusion of affected vertebrae and selection of valid alternative sites. Treat indicated osteoporosis separately from axSpA control.
Fractures, osteoporosis and neurological risk → Professional access required
6. Maintain safe longitudinal care
Follow pain, fatigue, sleep, participation, organ manifestations and medication safety alongside activity. Review smoking, blood pressure, cardiovascular risks and bone health. ACR vaccination guidance supports indicated pneumococcal and recombinant zoster vaccination during immunosuppressive care; live vaccines and medication timing need specific planning. Assign ownership of outstanding actions.
Make the follow-up record usable across teams: list current doses, interruptions, reasons for earlier discontinuations and the next monitoring action. Agree how the patient should report a suspected flare, infection or new organ symptom. Access difficulties and missed doses can imitate treatment failure; ask directly before concluding that an otherwise appropriate medicine has stopped working.
Discuss pregnancy and surgery before treatment interruptions. With sustained whole-disease control, a monitored taper may reduce burden. C-OPTIMISE supports reduction rather than withdrawal in selected responders, not one schedule for all agents. Specify the exact change, whether it is off-label, the review date and rescue plan; prompt recapture after relapse is not guaranteed.
Remission, tapering and the rescue plan → Professional access required
Selected sources
- ACR/SAA/SPARTAN 2026 summary. Posted June 24, 2026; summary-stage status verified October 4, 2026.
- ASAS–EULAR management recommendations, 2022 update.
- BSR targeted-therapy guideline, 2025.
- ASAS handbook. Historical methods reference for grading and instruments; current treatment guidance is cited separately.
- EULAR physical-activity recommendations: 2025 update, published 2026.
- SURPASS randomized comparison, 2024.
- ASAS difficult-to-manage and treatment-refractory definitions, 2025.
- AO Surgery Reference: fractures in the ankylosed cervical spine.
- Klingberg et al. Bone microarchitecture, fractures and syndesmophytes, 2013.
- ISCD Official Adult Positions, 2023.
- ACR vaccination guideline, 2022; published 2023.
- C-OPTIMISE dose-reduction trial, 2020.
The official ASDAS calculator and FDA drug-safety communication are linked in the relevant sections.